SLCO1B1 and Hyperbilirubinemia: The data seem compelling and showed dose-linear increase in AUCfrom 30 mg/kg to 1000 mg/kg (but not beyond) doses, and treatmentwas well tolerated with no cardiovascular events or renal toxicity(measured by KIM-1 molecule); however, it showed mild hyperbilirubinemia(dose-dependent increase in bilirubin) which is associated with itsstrong inhibition activity against blood transporter OATP1B1.79 Since then, Pfizer has made some organizationalchanges, and as a result the subsequent development of this projecthas been terminated (personal communication).